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Abstract
The c-Myc and human telomerase reverse transcriptase gene (hTERT) gene are frequently
deregulated and overexpressed in malignancy. hTERT activity is induced by c-Myc and strategies
designed to inhibit c-Myc expression in cancer cells may have considerable therapeutic value. We
designed and used a short hairpin RNA to inhibit c-Myc expression in Colo 320 cells and validated
its effect on cell proliferation. In this study, four c-Myc-shRNA expression vectors were
constructed and introduced into Colo 320 cells. The effects of c-Myc silencing on tumor cell
growth was assessed by soft agar assay and DNA synthesis experiments. The expressions of c-Myc
and hTERT were also assessed by real-time reverse transcription-polymerase chain reaction and
Western blot analysis. Upon transient transfection with plasmid encoding shRNA, it was found that
expression of c-Myc and hTERT decreased in shRNA-transfected cells. The downregulation of c-
Myc and hTERT inhibited cell growth, shortened telomere lengths, and suppressed telomerase
activity. In conclusion, our findings demonstrate that shRNA of c-Myc can inhibit the DNA
replication in Colo 320 cells effectively and reduce telomere length and telomerase activity,
therefore, it could be used as a new potential anticancer tool for therapy of human colon cancer.
Background
Telomerase is a ribonucleoprotein enzyme that synthe-
sizes telomeres, i.e., DNA repeats that cap and protect the
ends of chromosomes[1]. The core of the mammalian tel-
omerase holoenzyme is the catalytic subunit, telomerase
reverse transcriptase, which adds hexameric DNA repeats
(TTAGGG) that correspond to the telomerase RNA com-
ponent known as TERC[2,3]. Telomerase activation has
been regarded as a crucial step in cellular carcinogenesis,
and it is one of the most common molecular markers in a
broad spectrum of malignancies [4]. It has been reported
that telomerase activity is significantly high in about 80%
of cancers and correlates well with the degree of malig-
nancy[5]. Some studies have shown that hTERT gene
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activity in the diagnosis of malignant neoplasms, as the
hTERT gene is overexpressed in about 90% of malignant
tumors [6]. The control of c-Myc gene expression is a com-
plex process and occurs at various steps of transcription,
such as initiation, elongation, and attenuation, as well as
during the post-transcriptional stages[7,8].
The protein product of the c-Myc protooncogene plays a
vital role in the process of cellular growth and differentia-
tion[9]. Deregulation of c-Myc expression has been
detected in many cancers and is believed to be an impor-
tant step in carcinogenesis [10]. In addition, c-Myc has
also been implicated in the regulation of telomerase
through its ability to induce the transcriptional activation
of hTERT[11]. RNA interference (RNAi) has been
described.
Recently, a post-transcriptional gene silencing pathway
mediated by double-stranded RNA (dsRNA), also called
RNA interference (RNAi) has been described[12,13].
RNAi is a natural mechanism of defence, which protects
cells against exogenous dsRNA, such as viral or deriving
from transposones[14]. When a dsRNA enters the cyto-
plasm, RNAse III Dicer can process it to produce several
small interfering RNAs (siRNAs), 21–23 nucleotide long
RNA molecules with 2 nucleotide long 3'overhangs. Small
interfering RNAs may get incorporated into the RNA
induced silencing complex (RISC), which identifies and
silences complementary RNAs generally through a cleav-
age mechanism. In the last few years, it has been demon-
strated that siRNAs represent an efficient tool to modulate
the expression of a large number of cancer-related
genes[15].
In the present study, we selectively downregulated c-Myc
expression in human colon cancer Colo 320 cells with
siRNA delivered via a plasmid-based polymerase III pro-
moter system. This approach allowed us to explore a pos-
sible role for c-Myc in regulating telomerase activity.
Methods
Short-interfering RNA design
shRNA directed against c-Myc mRNA were selected using
the computer program (web site http://
www.ambion.com/techlib/misc/siRNA_finder.html),
and it was verified, by BLAST search, that there was no
homology with another human gene. shRNA #1–4
sequences directed against c-Myc mRNA were selected
according to Blast search score and GC content (40–60%).
The shRNA expression cassette contained 19 nucleotide of
the target sequence followed by the loop sequence
(TTCAAGACG), reverse complement to the 19 nucleotide,
stop codon for U6 promoter and BamHI site (c-Myc -1: 5'-
CTATGACCTCGACTACGACTTCAAGACCGTCCTAGTC-
GAGGTCATAG-3'; c-Myc -2: 5'-AAATTCGAGCTGCT-
GCCC TTCAAGACG GGGCAGCAGCTCGAATTTC-3'; c-
Myc -3: 5'GCCCCCAAGC TAGTTATC TTCAAGACG
GATAACTACCTTGGGGGCC-3'; c-Myc -4: 5'CCACAG-
CATACATCCTGT TTCAAGACG ACAGGATGTATGCTGT-
GGC-3'). The shRNA cassettes and their complementary
strands were synthesized (Wuhan Genesil Biotechnology,
Wuhan, China).
Cell culture and transfection
The colon cancer cell line Colo 320 was obtained from
China Center for TypeCulture Collection (GDC298). The
cells were grown in RPMI-1640 medium (GIBCO, Invitro-
gen, Carlsbad, CA) supplemented with 10% fetal bovine
serum (Gibco BRL), 50 units/ml penicillin, and 50 μg/ml
streptomycin. The Colo 320 cells were maintained in a
humidified 37°C incubator with 5% CO2, fed every 3
days with complete medium, and subcultured when con-
fluence was reached. The cells were routinely passaged
every 1 or 2 days. For transfection, 2 × 105 cells were
seeded into each well of a six well tissue culture plate
(Costar). The next day (when the cells were 70–80% con-
fluent), the culture medium was aspirated and the cell
monolayer was washed with pre-warmed sterile phos-
phate-buffered saline (PBS). Cells were transfected with
the pGensil-c-Myc -1, -2, 3, and -4 harboring green
pEGFP-C1 green fluorescence protein reporter gene by
using Lipofectamine 2000 reagent (Invitrogen, Carlsbad,
CA) in accordance with the manufacturer's protocol. Cells
were continuously cultured until harvest for analysis.
Cell counts
Colo 320 cells were trypsinized on the indicated days and
counted with a hemocytometer. We quantify cell prolifer-
ation by comparing the number of cells counted before
and after transfection. Colo 320 Approximately 200 cells
were evaluated in each sample using the hemocytometer.
cell viability was assessed by trypan blue exclusion
(Sigma-Aldrich China Inc, Shanghai, China).
DNA synthesis
Colo 320 cells were treated with 1 mCi of 3H-thymidine
per milliliter (Amersham Biosciences, Piscataway, NJ) for
the last 6 h of day 3 after shRNA treatment. Cells were
then rinsed twice with PBS, ice-cold 5% trichloroacetic
acid, and 80% ethanol; the incorporated radioactivity of
cell lysates was measured in a liquid scintillation counter.
Soft agar colony assay
Two days after transfection, Colo 320 cells (300 cells per
well) transfected with indicated plasmids were mixed with
tissue culture medium containing 0.7% agar to result in a
final agar concentration of 0.35%. Then 1 ml sample of
this cell suspension was immediately plated in six-well
plates coated with 0.6% agar in tissue culture medium (2Page 2 of 7
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weeks, the top layer of the culture was stained with 0.2%
piodonitrotetrazolium violet (Sigma). The culture was
analyzed in triplicate, and colonies larger than 100 μm in
diameter were counted.
Quantification of c-Myc and hTERT mRNA
For the sqRT-PCR analysis, total RNA was isolated using
Trizol reagent (Sigma) and reversely transcribed using
random hexamers with Superscript II (Invitrogen). For c-
Myc and hTERT detection, cDNA was mixed with the PCR
reaction mixture and each c-Myc and hTERT-specific
primer (LT5 and LT6). The PCR cycle number was set up
to permit the distinction between mRNA expression pro-
files among the samples. PCR products were visualized on
1.2% agarose gel. Actin was used as an internal control,
and positive and negative controls were always included.
PCR reagents were from the Master Taq kit (Eppendorf).
Telomere length measurement
Determination of telomere length was performed by
Southern analysis of telomere restriction fragment (TRF)
length. Genomic DNA was isolated from transfected cells
using DNA isolation kit (Qiagen, Valencia, CA, USA) and
quantified by UV spectrophotometry. Two micrograms of
DNA were digested with restriction endonucleases RsaI
and HinfI. The DNA digests were electrophoresed through
0.8% agarose and transferred to nylon membranes by cap-
illary transfer in 20 × SSC as described.
After UV crosslinking (1200 μJ), the membranes were
hybridized with a 3'-digoxigenin oligonucleotide probe
with the sequence (CCCTAA)3'. After washing to remove
unbound probe, an alkaline phosphatase-conjugated
anti-digoxigenin antibody (Roche Applied Science, Indi-
anapolis, IN, USA) was used for immunodetection of
bound probe, followed by CDP Star chemiluminescence
substrate (Roche Applied Science). Blots were exposed to
X-ray film for 10–60 s. Mean TRF length and percentage
photo-stimulated luminescence were determined from
densitometric analysis of digital images of exposed films
as described. Measurements of TRF length were performed
in duplicate for each membrane.
Detection of telomerase activity
The telomerase activity was measured using a PCR-TRAP
ELISA kit (Roche, USA) according to the manufacturer's
description with some modifications. For the TRAP reac-
tion, 2 μg total RNA was added to 25 μl of reaction mix-
ture with the appropriate amount of sterile water to create
a final volume of 50 μl. Hybridization and the ELISA reac-
tion were carried out following the manufacturer's
instructions.
Western blotting
Transfected cells were washed twice with PBS and sus-
pended in IPH lysis buffer (50 mM Tris (pH 8.0), 150 mM
NaCl, 5 mM EDTA, 0.5% NP40, 100 mM phenylmethyl
sulfonyl fluoride leupeptin 1 mg/mL, aprotinin 1 mg/mL,
and 1 M dithiothreitol). Cells were extracted at 4°C for 30
min. After centrifugation at 12,000 rpm for 20 min, the
supernatant was subject to electrophoresis on 10%
sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE),
and transferred to a polyvinylidene difluoride (PVDF)
membrane. The membrane was allowed to react with anti-
β-actin polyclonal, anti-c-Myc and hTERT antibody (Santa
Cruz Biotechnology). Specific antibodies were detected
with a chemiluminescence kit (Sigma Life Science)
according to the supplier's manual. Chemiluminescence
was detected by exposure to X-ray film.
Statistical analysis
All data in the text and figures is presented as means ±
standard deviation (means ± SD). Statistical analysis was
performed using Student's t-test.
Results
Effect of the c-Myc small interfering RNA on cell growth
As the first step, transfection efficiency of the plasmid
encoding shRNA for c-Myc in Colo 320 cells was exam-
ined by coexpressing pEGFP green fluorescence protein.
When the cells were examined under a fluorescence
microscope 24 h after transfection, more than 75–85% of
them was transfected (Figure 1A).
We then tested whether RNAi-mediated c-Myc could
influence the ability of Colo 320 cells to form colonies in
soft agar. Colo 320 cells were transfected with pGensil-c-
Myc or empty vector. At 48 hours after transfection, the
cells were placed into medium with soft agar, and colo-
nies were counted after 2 weeks. RNAi directed against c-
Myc resulted in a significant decrease (about 65%) in col-
ony formation in Colo 320 cells (Figure 1B-1,2,3). These
results showed that suppression of c-Myc by RNAi could
decrease the ability of colon cancer cells to form colonies
in soft agar.
Since four constructs gave similar results, we describe the
results with pGenesil – c-Myc -1 in the subsequent exper-
iments. We also evaluated the effect of c-Myc-specific
shRNA on Colo 320 cell proliferation. Cell proliferation
was measured by counting the number of viable cells
using trypan blue staining. Transfected c-Myc-shRNA (Fig-
ure 1C-1) resulted in a marked inhibition of cell prolifer-
ation over this 2-day period and the shRNAs induced anti-
proliferative effect was dose dependent. Cell growth was
not influenced significantly by treatment with control-
shRNA and vector. The statistical analysis shows that Colo
320 cell proliferation was affected by silencing of c-Myc.Page 3 of 7
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3H-thymidine. In Figure 1C-2, the cell control and vector
showed the maximum counts of (3H) thymidine (around
1400 and 1350 cpm/μgDNA) when compared to the
treatment groups. In addition, the anti-proliferative effect
was dose dependent and maximum inhibition was
achieved with 12.5 μM shRNA.
Down-regulation of c-Myc and hTERT by expression of 
shRNA
Compared with untreated cells, c-Myc and hTERT mRNA
abundance was significantly decreased in cells incubated
with 5, 7.5, 10, or 12.5 μM shRNA for 48 h (P < 0.01).
Control and empty vector group markedly expressed c-
Myc mRNA (Figure 2A) (P < 0.01).
As Western blot analysis indicated, the shRNA was able to
reduce c-Myc and hTERT protein expression. As indicated
in (Figure 2B), shRNA treatment inhibited the protein
expression levels of c-Myc genes, representative down-
stream targets for c-Myc and hTERT protein in Colo 320
cells (P < 0.01). Transfection with shRNA at different con-
centrations (0, 5,7.5, 10, 12.5) resulted in the significant
attenuation of expression of c-Myc and hTERT protein (P
< 0.01). In contrast, β-actin protein expression was not
affected by shRNA. These data indicated that vector-based
Effect of shRNA on proliferation of Colo 320 cellsFigure 1
Effect of shRNA on proliferation of Colo 320 cells. A. Plasmid pGenesil-c-Myc-1,-2, -3, and -4 with pEGFP encoding 
green fluorescence protein were transfected to the cells. B. c-Myc-depletion inhibits colony formation of Colo 320 cells. B-1) 
Control Colo 320 cells. B-2) Colo 320 cells treated with pGenesil-c-Myc-1 for 24 h B-3) The percentage of colonies of pGen-
esil-c-Myc-1 treated cells standardized against the corresponding control. C. Cells were treated with increasing concentrations 
of shRNA for 48 h. C-1)Cell viability was determined by cell counts. Results are expressed as the percentage of viable cells in 
the treatment groups with respect to that in the corresponding control. C-2) Cell proliferation following shRNA treatments 
for 48 h was quantified by 3H-thymidine incorporation studies. All data were obtained from three independent experiments. 
Error bars represent means ± SEM. Significantly different from the corresponding control (**P < 0.01, vs control. ##P < 0.01, 
vs vector).Page 4 of 7
(page number not for citation purposes)
Journal of Experimental & Clinical Cancer Research 2008, 27:27 http://www.jeccr.com/content/27/1/27RNAi could effectively suppress c-Myc and hTERT over-
expression.
Effects of shRNA on telomere length and telomerase 
activity
We evaluated the effect of shRNA on telomerase activity.
Our data suggested that shRNA could down-regulate tel-
omerase activity in shRNA-transfected groups. Telomerase
activity were shown in Figure 3A. It revealed that shRNA-
transfected groups had lower telomerase activity than the
control groups. shRNA at a variety of concentrations
resulted in significant reduction of telomerase activity.
TRF length then was determined using pulse gel electro-
phoresis followed by Southern blot hybridization with
telomere-specific probes. Average telomere length is
shown in Figure 3B-1. Telomere length in shRNA-trans-
fected groups telomeres was shorter than the one in the
control groups. Transfection of shRNA resulted in signifi-
cant increment of mean telomere length (Figure 3B-2, P <
0.05).
Discussion
Some researchers have shown that c-Myc act as a transcrip-
tion factor, which binds with E-box sites (CACGTG) of a
gene's cis-element to regulate other gene transcription,
such as hTERT gene[16]. C-Myc forms a dimer with Max,
then binds to the specific E-box site sequence 5'-CACGTG-
3' to transactivate target genes[17]. In contrast, c-Myc may
also form a dimer with mad1 at the same binding site to
suppress the transcription of target genes[18].
It has been shown that telomerase is highly related with
malignant neoplasms [19]. When cells change from the
normal growth status to abnormal growth status, there is
persistent telomerase activity[20]. Previous studies
showed that hTERT expression is related to many factors;
in particular, that hTERT transcript regulation is affected
Effect of shRNA on expression of c-Myc and hTERT gene in Colo 320 cellsFigure 2
Effect of shRNA on expression of c-Myc and hTERT gene in Colo 320 cells. A. c-Myc and hTERT mRNA expression 
of Colo 320 cells was detected by RT-PCR with different treatments. The cells were subjected to no treatment (control), 
pGenesil-vector group, 5, 7.5, 10, 12.5 μM shRNA for 48 h. B. c-Myc protein and hTERT expression of Colo 320 cells was 
detected by Western blotting with different treatments. Typical Western blot results for c-Myc and hTERT protein. Protein 
expression of c-Myc in Colo 320 cells was quantified by densitometric analysis. All data were obtained from three independent 
experiments. Error bars represent means ± SEM. Significantly different from the corresponding control (**P < 0.01, vs control. 
##P < 0.01, vs vector).Page 5 of 7
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Others report that activation or inhibition of c-Myc
expression can change hTERT promoter activity[23,24].
The up-regulation, of c-Myc can trans-activate hTERT pro-
moter and consequently activates telomerase. Xu et al sug-
gest that c-Myc can activate hTERT transcription in a dose-
dependent manner in leukemia cells. Several studies have
shown that downregulating c-Myc activity induces tumor
shrinkage[25].
In the present study, we used vector-based shRNA tech-
nique and constructed the recombinant plasmid express-
ing c-Myc-shRNA to transfect Colo 320 cells. Our results
demonstrated that a transient reduction of c-Myc protein
level by RNAi could significantly inhibit the growth rate of
Colo 320 cells and its ability to form colonies in soft agar.
Based on the results of western blotting, we also con-
firmed that the specific c-Myc-shRNA designed and used
in this study successfully reduce the expression of the c-
Effects of shRNA on telomere length and telomerase activity in Colo 320 cellsFigure 3
Effects of shRNA on telomere length and telomerase activity in Colo 320 cells. A. Representative the concentra-
tion-course analysis of telomerase activity, each groups cells were mixed with 1 ml TBA solution for preparation of protein 
extract and 1 μg protein was subjected to TRAP assay. After hybridization and ELISA procedure, the absorbance of the sam-
ples at 450 nm was measured. The cells were subjected to no treatment (control), pGenesil-vector group, 5, 7.5, 10, 12.5 μM 
shRNA for 48 h. B. Mean telomere restriction fragment length was detected by RT-PCR with different treatments by Southern 
analysis as described under Materials and methods. Typical Southern blot results for telomere restriction fragments. Locations 
of the base pair markers on the DNA ladder are indicated along the left side. Significant difference was observed between the 
mean telomere lengths of the control and shRNA-transfected groups cells. All data were obtained from three independent 
experiments. Error bars represent means ± SEM. Significantly different from the corresponding control (**P < 0.01, vs control. 
##P < 0.01, vs vector).Page 6 of 7
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Myc and hTERT. We also found the We also found the
attenuation of c-Myc and hTERT protein expression was
dose-dependent.
Telomerase activity is strongly associated with telomere
length maintenance. In the present study, we analyzed tel-
omere length and telomerase activity in shRNA-trans-
fected Colo 320 cells. Fig. 3 shows that the shRNA-
transfected group had a shorter telomere length and lower
telomerase activity than control group. Therefore, shRNA
can significantly reduce telomere length and telomerase
activity in siRNA-transfected Colo 320 cells.
In summary, we have identified the c-Myc shRNA that spe-
cifically inhibits activated c-Myc and suppresses cell pro-
liferation. The c-Myc shRNA is able to block c-Myc DNA-
binding activity and reduces the levels of c-Myc mRNA.
Meanwhile, c-Myc shRNA can significantly reduce tel-
omere length and telomerase activity in shRNA-trans-
fected Colo 320 cells. Targeting c-Myc activation with
RNAi may hold therapeutic promise for colon cancer with
c-Myc and telomerase activation.
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